Anadys Starts Hep C Trial
Luke Timmerman9/9/09
San Diego-based Anadys Pharmaceuticals (NASDAQ: ANDS) said today it has started a mid-stage clinical trial of its lead drug candidate, ANA598, for patients with hepatitis C. The study will enroll 90 patients on the drug or a placebo, in combination with the standard treatments—pegylated interferon alpha and ribavirin. Initial results on the anti-viral activity of the Anadys drug should be available by year-end, with more follow-up data to come in 2010, the company said. This ambitious trial design is part of what has brought Anadys back from some dark days earlier this year.
